The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis.

[1]  Javed Siddiqui,et al.  Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. , 2016, European urology.

[2]  Saila Kauppila,et al.  Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. , 2016, European urology.

[3]  P. Mulders,et al.  The value of magnetic resonance imaging and ultrasonography (MRI/US)‐fusion biopsy platforms in prostate cancer detection: a systematic review , 2016, BJU international.

[4]  H. Cammann,et al.  The percentage of prostate‐specific antigen (PSA) isoform [–2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years , 2016, BJU international.

[5]  C. Roehrborn,et al.  Assessment of Prospectively Assigned Likert Scores for Targeted Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsies in Patients with Suspected Prostate Cancer. , 2016, The Journal of urology.

[6]  P L Choyke,et al.  PI-RADS version 2: what you need to know. , 2015, Clinical radiology.

[7]  A. Cheng,et al.  The state of TRUS biopsy sepsis: readmissions to Victorian hospitals with TRUS biopsy‐related infection over 5 years , 2015, BJU international.

[8]  P. Choyke,et al.  Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. , 2015, Urologic oncology.

[9]  N. Keating,et al.  Treatment patterns for older veterans with localized prostate cancer. , 2015, Cancer epidemiology.

[10]  D. Margolis,et al.  Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology. , 2015, Urology.

[11]  Pierre Mozer,et al.  Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. , 2015, The Journal of urology.

[12]  G. Cuckler,et al.  National health expenditure projections, 2014-24: spending growth faster than recent trends. , 2015, Health Affairs.

[13]  M. Vural,et al.  Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit? , 2015, Diagnostic and interventional radiology.

[14]  M. Roethke,et al.  Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance , 2015, Prostate Cancer and Prostatic Disease.

[15]  C. Magi-Galluzzi,et al.  Novel biomarkers and genomic tests in prostate cancer: a critical analysis. , 2015, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[16]  C. Roehrborn,et al.  Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy. , 2015, Urologic oncology.

[17]  L. Kavoussi,et al.  In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12‐core biopsy still necessary in addition to a targeted biopsy? , 2015, BJU international.

[18]  Ivan Pedrosa,et al.  MR Imaging-Transrectal US Fusion for Targeted Prostate Biopsies: Implications for Diagnosis and Clinical Management. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[19]  Massimo Mischi,et al.  Multiparametric ultrasound in the detection of prostate cancer: a systematic review , 2015, World Journal of Urology.

[20]  Baris Turkbey,et al.  Recent advances in image-guided targeted prostate biopsy , 2015, Abdominal Imaging.

[21]  A. Fenster,et al.  Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. , 2015, AJR. American journal of roentgenology.

[22]  E. Steyerberg,et al.  The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. , 2014, European urology.

[23]  A. Ouzzane,et al.  Multiparametric MRI-Targeted TRUS Prostate Biopsies Using Visual Registration , 2014, BioMed research international.

[24]  Y. Yamashita,et al.  Negative predictive value of multiparametric MRI for prostate cancer detection: outcome of 5-year follow-up in men with negative findings on initial MRI studies. , 2014, European journal of radiology.

[25]  Andrew B Rosenkrantz,et al.  Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. , 2014, The Journal of urology.

[26]  P. Carroll,et al.  Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[27]  M. Emberton.  Is prostate magnetic resonance imaging going to break the bank? , 2014, European urology.

[28]  Maarten de Rooij,et al.  Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. , 2014, European urology.

[29]  C. Roehrborn,et al.  Multiparametric Magnetic Resonance Imaging of the Prostate: Technical Aspects and Role in Clinical Management , 2014, Topics in magnetic resonance imaging : TMRI.

[30]  M. Stifelman,et al.  A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. , 2014, European urology.

[31]  F. Schröder,et al.  Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. , 2014, European urology.

[32]  Baris Turkbey,et al.  Comparison of endorectal coil and nonendorectal coil T2W and diffusion‐weighted MRI at 3 Tesla for localizing prostate cancer: Correlation with whole‐mount histopathology , 2014, Journal of magnetic resonance imaging : JMRI.

[33]  Baris Turkbey,et al.  Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. , 2014, The Journal of urology.

[34]  M. Wirth,et al.  Re: Early Detection of Prostate Cancer: AUA Guideline , 2014 .

[35]  W. Rogowski,et al.  The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer , 2014, BMC Health Services Research.

[36]  John Jesitus,et al.  MRI guiding future of prostate cancer diagnosis , 2014 .

[37]  Young Hwan Kim,et al.  Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection. , 2014, Radiology.

[38]  Jurgen J Fütterer,et al.  Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. , 2014, AJR. American journal of roentgenology.

[39]  P. Carroll,et al.  Prostate cancer early detection version 1 , 2014 .

[40]  J. Rubenstein.  How to Code for Magnetic Resonance Imaging-informed Prostate Biopsies. , 2014, Reviews in urology.

[41]  C. Gross,et al.  The cost implications of prostate cancer screening in the Medicare population , 2014, Cancer.

[42]  Yair Lotan,et al.  Systematic review of complications of prostate biopsy. , 2013, European urology.

[43]  A. Stephenson,et al.  Re: Early Detection of Prostate Cancer: AUA Guideline , 2013 .

[44]  Baris Turkbey,et al.  Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. , 2013, European urology.

[45]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[46]  I. Thompson,et al.  The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate‐specific antigen and biopsy outcome , 2013, Cancer.

[47]  Xavier Leroy,et al.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. , 2013, Radiology.

[48]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[49]  S. Kaplan,et al.  Consideration of comorbidity in risk stratification prior to prostate biopsy , 2013, Cancer.

[50]  M. Soloway,et al.  Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. , 2013, Urologic oncology.

[51]  J. Ward,et al.  PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. , 2013, The Journal of urology.

[52]  L. Salomon,et al.  Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow‐up from a prospective trial , 2013, BJU international.

[53]  C Fraser,et al.  The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. , 2013, Health technology assessment.

[54]  Robert D. Lieberthal,et al.  Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. , 2013, American health & drug benefits.

[55]  M. Dall’Era.  The economics of active surveillance for prostate cancer , 2013, Current opinion in urology.

[56]  N. Giménez,et al.  Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis , 2012, Clinical chemistry and laboratory medicine.

[57]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[58]  J. Pépin,et al.  Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? , 2012, European urology.

[59]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[60]  M. Pearle,et al.  Cost‐effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)‐guided prostate biopsy prophylaxis , 2012, BJU international.

[61]  S. Madersbacher,et al.  Re: Thomas Hambrock, Caroline Hoeks, Christina Hulsbergen-van de Kaa, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012;61:17 , 2012, European urology.

[62]  E. Klein,et al.  High-Grade Prostatic Intraepithelial Neoplasia , 2012, Korean journal of urology.

[63]  J. Cashy,et al.  Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. , 2012, The Journal of urology.

[64]  Thomas Hambrock,et al.  Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. , 2012, European urology.

[65]  Baris Turkbey,et al.  Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. , 2011, The Journal of urology.

[66]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[67]  Baris Turkbey,et al.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? , 2011, Radiology.

[68]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[69]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[70]  Peter H Gann,et al.  Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[72]  T. H. van der Kwast,et al.  False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up , 2010, The American journal of surgical pathology.

[73]  P. Choyke,et al.  Is Apparent Diffusion Coeffi cient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images ? 1 , 2010 .

[74]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[76]  H. D. de Koning,et al.  Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer , 2009, British Journal of Cancer.

[77]  Raphael Bueno,et al.  Prostate biopsy: past, present, and future. , 2007, Urology.

[78]  D. Beyersdorff,et al.  MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. , 2005, AJR. American journal of roentgenology.

[79]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[80]  M. Roobol,et al.  Prevalence and characteristics of screen‐detected prostate carcinomas at low prostate‐specific antigen levels: aggressive or insignificant? , 2005, BJU international.

[81]  M. Kattan,et al.  A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. , 2009, The Journal of urology.

[82]  W. Catalona.  A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session: Editorial comment , 2003 .